Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tocilizumab biosimilar - Fresenius Kabi

Next Previous
Drug Profile

Tocilizumab biosimilar - Fresenius Kabi

Alternative Names: MSB-11456; Tyenne

Latest Information Update: 30 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck KGaA
  • Developer Fresenius Kabi
  • Class Anti-inflammatories; Antineoplastics; Antirheumatics; Antivirals; Immunotherapies; Monoclonal antibodies; Skin disorder therapies; Urologics; Vascular disorder therapies
  • Mechanism of Action Interleukin 6 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Autoimmune disorders; COVID 2019 infections; Cytokine release syndrome; Giant cell arteritis; Juvenile rheumatoid arthritis; Rheumatoid arthritis

Most Recent Events

  • 14 Nov 2024 Efficacy, safety and immunogenicity data from the phase III APTURA I trial in Rheumatoid arthritis presented at the ACR Convergence 2024 (ACR-2024)
  • 28 Oct 2024 No recent reports of development identified for phase-I development in Rheumatoid-arthritis(In volunteers) in Unknown (IV)
  • 17 Oct 2024 Launched for COVID-2019 infections in Canada (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top